Algorithme Pharma Announces a Strategic Appointment

Laval, Canada, May 12, 2010 (ots/PRNewswire) - Doug Peel, Executive
Chairman of the Board of Directors of Algorithme Pharma, is pleased
to announce the appointment of Christopher Perkin as the company's
President and Chief Executive Officer. Mr. Perkin will officially
join the company on May 31st.

This important appointment confirms Algorithme Pharma's
commitment to the development of innovative strategies to better
serve its clients and business partners. It also reflects the
company's on- going efforts to become a world leader in clinical
research and bioanalysis.

A native of England with a solid scientific background,
Christopher Perkin is a seasoned executive and recognized leader with
more than 30 years' experience in pharmaceutical development and
business strategy. After holding several key positions at Huntingdon
Research Center and Beecham Pharmaceuticals, Mr. Perkin joined the
Charles River Laboratories in Senneville, Quebec, Canada, where he
rose through the ranks to Corporate Senior Vice President - Global
Preclinical Services with responsibility for operations in Asia and
North America.

"Mr. Perkin is a highly talented individual with world-class
experience in our industry, and I am confident he wil create a
dynamic environment with a renewed business focus that wil reinforce
our industry-leading position and assure our status as a key
international partner of pharmaceutical companies," said Doug Peel,
Executive Chairman of the Board of Algorithme Pharma Holdings Inc.

About Algorithme Pharma

As a major global player in clinical research and bioanalysis,
Algorithme Pharma provides a wide range of services for
bioequivalence and early stage development (Phase I/IIa) studies to
the pharmaceutical, and biotechnology industries. In addition to its
multi-unit clinical facilities in Canada and the United Kingdom
(more than 250 beds) and with its new dedicated Montreal
state-of-the-art facility for Phase I clinical studies, Algorithme
Pharma offers different services including protocol designs, CTD/ICH
clinical reports, data management, biostatistics, quality assurance
and regulatory affairs. Successfully audited by the US FDA, Canada
TPD, Brazil ANVISA, France AFSSAPS, UK MHRA and Austria AGES
regulatory authorities, Algorithme Pharma conducts over 275 clinical
trials per year. For further information: Mme Marie-Claude
Boisvert, Vice President, Kilmer Capital Partners,
+1-(514)-973-6077; http://www.algopharm.com

ots Originaltext: Algorithme Pharma
Im Internet recherchierbar: http://www.presseportal.de

Contact:
CONTACT: For further information: Mme Marie-Claude Boisvert,
VicePresident, KilmerCapital Partners,
+1-(514)-973-6077;http://www.algopharm.com